User login
Antirougeurs FORT Relief Concentrate
Pierre Fabre Dermo-Cosmétique USA introduces Avène Antirougeurs FORT Relief Concentrate for chronic redness. This advanced spot treatment is indicated for localized redness and small visible blood vessels, chronic persistent to permanent redness, and rosacea. It is formulated with Ruscus extract (0.3%) to induce contraction of the smooth muscle in blood vessel walls to encourage microcirculation and inhibit the formation of new blood vessels. Results have been seen after 3 months of once nightly application. Antirougeurs FORT Relief Concentrate is available exclusively in physicians’ offices. For more information, visit www.aveneusa.com.
Cosentyx
Novartis Pharmaceuticals Corporation announces US Food and Drug Administration approval of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is a human monoclonal antibody that selectively binds to IL-17A and inhibits its reaction with the IL-17 receptor. For more information, visit www.novartis.com.
DEJ Face Cream
Revision Skincare adds DEJ face cream to the antiaging collection. It is formulated with rosemary extract, goji fruit extract, coenzyme Q10, and vitamins C and E for antioxidant benefits. The cream also contains peptides palmitoyl tripeptide-38 and acetyl tetrapeptide-2 to tighten the dermoepidermal junction and reduce the appearance of fine lines and wrinkles as well as a copper complex to provide energy to aging cells. A blend of 3 ceramides provides moisturization. Results have shown a reduction in redness, hyperpigmentation, and fine lines and wrinkles, as well as better overall appearance. DEJ face cream is available exclusively through dermatologists, plastic surgeons, and medical spas, and can be layered with other products. For more information, visit www.revisionskincare.com.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
Antirougeurs FORT Relief Concentrate
Pierre Fabre Dermo-Cosmétique USA introduces Avène Antirougeurs FORT Relief Concentrate for chronic redness. This advanced spot treatment is indicated for localized redness and small visible blood vessels, chronic persistent to permanent redness, and rosacea. It is formulated with Ruscus extract (0.3%) to induce contraction of the smooth muscle in blood vessel walls to encourage microcirculation and inhibit the formation of new blood vessels. Results have been seen after 3 months of once nightly application. Antirougeurs FORT Relief Concentrate is available exclusively in physicians’ offices. For more information, visit www.aveneusa.com.
Cosentyx
Novartis Pharmaceuticals Corporation announces US Food and Drug Administration approval of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is a human monoclonal antibody that selectively binds to IL-17A and inhibits its reaction with the IL-17 receptor. For more information, visit www.novartis.com.
DEJ Face Cream
Revision Skincare adds DEJ face cream to the antiaging collection. It is formulated with rosemary extract, goji fruit extract, coenzyme Q10, and vitamins C and E for antioxidant benefits. The cream also contains peptides palmitoyl tripeptide-38 and acetyl tetrapeptide-2 to tighten the dermoepidermal junction and reduce the appearance of fine lines and wrinkles as well as a copper complex to provide energy to aging cells. A blend of 3 ceramides provides moisturization. Results have shown a reduction in redness, hyperpigmentation, and fine lines and wrinkles, as well as better overall appearance. DEJ face cream is available exclusively through dermatologists, plastic surgeons, and medical spas, and can be layered with other products. For more information, visit www.revisionskincare.com.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
Antirougeurs FORT Relief Concentrate
Pierre Fabre Dermo-Cosmétique USA introduces Avène Antirougeurs FORT Relief Concentrate for chronic redness. This advanced spot treatment is indicated for localized redness and small visible blood vessels, chronic persistent to permanent redness, and rosacea. It is formulated with Ruscus extract (0.3%) to induce contraction of the smooth muscle in blood vessel walls to encourage microcirculation and inhibit the formation of new blood vessels. Results have been seen after 3 months of once nightly application. Antirougeurs FORT Relief Concentrate is available exclusively in physicians’ offices. For more information, visit www.aveneusa.com.
Cosentyx
Novartis Pharmaceuticals Corporation announces US Food and Drug Administration approval of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is a human monoclonal antibody that selectively binds to IL-17A and inhibits its reaction with the IL-17 receptor. For more information, visit www.novartis.com.
DEJ Face Cream
Revision Skincare adds DEJ face cream to the antiaging collection. It is formulated with rosemary extract, goji fruit extract, coenzyme Q10, and vitamins C and E for antioxidant benefits. The cream also contains peptides palmitoyl tripeptide-38 and acetyl tetrapeptide-2 to tighten the dermoepidermal junction and reduce the appearance of fine lines and wrinkles as well as a copper complex to provide energy to aging cells. A blend of 3 ceramides provides moisturization. Results have shown a reduction in redness, hyperpigmentation, and fine lines and wrinkles, as well as better overall appearance. DEJ face cream is available exclusively through dermatologists, plastic surgeons, and medical spas, and can be layered with other products. For more information, visit www.revisionskincare.com.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
